Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab deruxtecan + capecitabine + durvalumab
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Trastuzumab deruxtecan + capecitabine + durvalumab is an investigational combination therapy being evaluated in clinical trials for the treatment of HER2-positive and HER2-low advanced gastric, gastroesophageal junction, and breast cancer. Trastuzumab deruxtecan is an antibody-drug conjugate targeting HER2, consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload via a cleavable tetrapeptide linker, designed to deliver cytotoxic activity directly to HER2-expressing cancer cells. Capecitabine is an oral fluoropyrimidine carbamate that functions as a prodrug of 5-fluorouracil and disrupts DNA synthesis through inhibition of thymidylate synthase. Durvalumab is an immune checkpoint inhibitor that binds to PD-L1, preventing interaction with PD-1 and CD80, thereby promoting anti-tumor immune responses. This combination is developed for neoadjuvant, perioperative, and advanced settings to exploit synergistic cytotoxicity and immune modulation.[2][3][4][7]
- Brand names
- EnhertuImfinziXeloda
- Other names
- trastuzumab deruxtecan + capecitabine + durvalumab
02
Targets
TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on trastuzumab deruxtecan + capecitabine + durvalumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab deruxtecan + capecitabine + durvalumab.